Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
|Articles|March 24, 2020
PsychPearls: Battling Anxiety During the COVID-19 Pandemic
Author(s)Joshua C. Morganstein, MD
How can psychiatrists advise patients to manage their stress and to remain calm?
Advertisement
Dr Joshua Morganstein, Chair of the American Psychiatric Association Committee on the Psychiatric Dimensions of Disaster, answers this question: There is a lot of panic, and anxiety/stress is on the rise, even in people without mental illness. How can psychiatrists advise patients to manage this stress and to remain calm?
Have more COVID concerns and clinical tips? Email us at
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
5